ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

DNA

Shape Therapeutics launches with $35.5 million for RNA-editing therapies

by Ryan Cross
November 9, 2019 | APPEARED IN VOLUME 97, ISSUE 44

 

Seattle-based Shape Therapeutics has raised $35.5 million in series A financing to develop RNA-editing therapies. Unlike DNA, RNA is made continually in the cell, so some scientists view RNA editing as potentially safer than gene editing. Shape was cofounded by University of California San Diego scientist Prashant Mali. His lab has designed synthetic RNA molecules that direct enzymes called ADAR to make precise, single-letter changes to RNA in human cells. Mali’s lab has already tested the technique in a mouse model of muscular dystrophy.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment